1. The activated conformation of integrin [beta]7 is a novel multiple myeloma-specific target for CAR T cell therapy
- Author
-
Hosen, Naoki, Matsunaga, Yukiko, Hasegawa, Kana, Matsuno, Hiroshi, Nakamura, Yuki, Makita, Mio, Watanabe, Kouki, Yoshida, Mikako, Satoh, Kei, Morimoto, Soyoko, Fujiki, Fumihiro, Nakajima, Hiroko, Nakata, Jun, Nishida, Sumiyuki, Tsuboi, Akihiro, Oka, Yoshihiro, Manabe, Masahiro, Ichihara, Hiroyoshi, Aoyama, Yasutaka, Mugitani, Atsuko, Nakao, Takafumi, Hino, Masayuki, Uchibori, Ryosuke, Ozawa, Keiya, Baba, Yoshihiro, Terakura, Seitaro, Wada, Naoki, Morii, Eiichi, Nishimura, Junichi, Takeda, Kiyoshi, Oji, Yusuke, Sugiyama, Haruo, Takagi, Junichi, and Kumanogoh, Atsushi
- Subjects
Structure ,Care and treatment ,Physiological aspects ,Genetic aspects ,Research ,Immunotherapy -- Health aspects -- Genetic aspects -- Research ,Multiple myeloma -- Genetic aspects -- Care and treatment -- Research ,Integrins -- Physiological aspects -- Structure -- Genetic aspects -- Research ,T cells -- Health aspects -- Physiological aspects -- Genetic aspects -- Research - Abstract
Author(s): Naoki Hosen (corresponding author) [1, 2, 3]; Yukiko Matsunaga [4]; Kana Hasegawa [1]; Hiroshi Matsuno [5]; Yuki Nakamura [1]; Mio Makita [1]; Kouki Watanabe [1]; Mikako Yoshida [1]; Kei [...], Cancer-specific cell-surface antigens are ideal targets for monoclonal antibody (mAb)-based immunotherapy but are likely to have previously been identified in transcriptome or proteome analyses. Here, we show that the active conformer of an integrin can serve as a specific therapeutic target for multiple myeloma (MM). We screened [greater than] 10,000 anti-MM mAb clones and identified MMG49 as an MM-specific mAb specifically recognizing a subset of integrin [beta][sub.7] molecules. The MMG49 epitope, in the N-terminal region of the [beta][sub.7] chain, is predicted to be inaccessible in the resting integrin conformer but exposed in the active conformation. Elevated expression and constitutive activation of integrin [beta][sub.7] conferred high MMG49 reactivity on MM cells, whereas MMG49 binding was scarcely detectable in other cell types including normal integrin [beta][sub.7][sup.+] lymphocytes. T cells transduced with MMG49-derived chimeric antigen receptor (CAR) exerted anti-MM effects without damaging normal hematopoietic cells. Thus, MMG49 CAR T cell therapy is promising for MM, and a receptor protein with a rare but physiologically relevant conformation can serve as a cancer immunotherapy target.
- Published
- 2017
- Full Text
- View/download PDF